A 57-year-old man presented with a left cervical lymph node mass. The surgical specimen yielded a combined (composite) lymphoma. Investigators reported that the lesion was composed of two distinct lymphoma components: a follicular-pattern disease and an early-phase mantle cell component. The abstract did not provide the patient’s broader clinical history, laboratory data, or initial staging studies beyond the lymph node and subsequent marrow assessment.
Microscopic evaluation showed complete effacement of the lymph node architecture with a blurred, follicle-like nodular distribution. The nodules consisted predominantly of centrocytes and centroblasts together with small lymphocytes with mildly irregular nuclei. Mantle-zone architecture was not prominent on light microscopy. Immunohistochemical staining produced a mixed phenotype. Tumor cells were diffusely and strongly positive for CD20, consistent with B-cell lineage. Cells within the follicle-like nodules expressed CD10, bcl-6 and bcl-2. A smaller population of cells expressed CD5 and Cyclin D1; these CD5/Cyclin D1-positive cells were relatively sparse and localized chiefly to cuff-like regions adjacent to the follicle-like nodules. The source did not report quantitative percentages for IHC positivity or provide photomicrograph details in the abstract.
Fluorescence in situ hybridization (FISH) testing detected rearrangements of both bcl-2 and CCND1 genes in the lymph node specimen. Immunoglobulin heavy-chain (IgH) gene clonality analysis revealed two different monoclonal peaks, which the authors interpreted as evidence for two separate neoplastic clones rather than evolution of a single clone. Next-generation sequencing (NGS) identified a CCND1 gene mutation and confirmed a bcl-2 IgH rearrangement. The abstract did not specify the NGS panel composition, variant nomenclature, allele frequencies, or depth of coverage; those methodological details were not reported in the available summary.
Bone marrow biopsy was performed and indicated involvement by the mantle cell lymphoma component. The report in the abstract did not include marrow cellularity metrics, percent infiltration, immunophenotypic flow cytometry data, or cytogenetic karyotype. Clinical staging, performance status, or systemic symptoms were not detailed in the abstract, so implications for stage-directed therapy and prognostic stratification must be inferred cautiously and are not provided by the source.
The case required integration of morphology, immunophenotype and molecular genetics to reach the diagnosis of composite lymphoma comprising follicular lymphoma and mantle cell lymphoma. Authors noted that the two components can overlap morphologically, necessitating targeted immunostains and genetic assays to separate them from mimics such as transformed follicular lymphoma with aberrant marker expression or CD5-positive follicular variants. The detection of distinct IgH monoclonal peaks supported independent clonal origins. The abstract mentioned discussion of differential diagnoses, potential biological significance and clinical management strategies; however, the authors did not list specific therapeutic regimens or outcomes in the abstract. MeSH indexing suggested consideration of agents such as doxorubicin and prednisone, but the source did not state whether these or other chemotherapy protocols were used for this patient.
The published abstract is concise and leaves several items unspecified. It did not provide full clinical context (symptoms, laboratory values, imaging or formal stage), detailed IHC quantitation, photographic documentation, or the full molecular report with exact variants and assay parameters. Treatment selection and clinical follow-up data, including response and survival, were not reported in the abstract. The authors declared no conflicts of interest. Remaining questions that the source did not answer include whether the two clones arose synchronously or sequentially, how the identification of discrete clones influenced therapeutic choices, and what the patient’s clinical course was after diagnosis. These gaps limit prognostic and management inferences from the abstract alone.